


Claims

1. A compound having the general formula (I):

5




wherein:


R¹ is selected from the group consisting of:

10

-H and C₁-C₆-alkyl, aryl, or



wherein R¹⁸ is selected from the group consisting of



wherein R¹⁹ is independently selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO₂, -NH₂ or -CF₃,


15

R² is selected from the group consisting of:

-H and C₁-C₆-alkyl,

R^3 , R^4 , R^5 and R^6 are independently selected from the group consisting of:

-H, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, phenoxy, -F, -Cl, -Br, -I, -OH, -CN, - $NR^{12}R^{12'}$, - $N=N-R^{13}$, - $NH-C(O)-R^{14}$, - NO_2 , - $C\equiv C-R^{15}$, - $C(R^{20})_3$, or - $CH(R^{20})_2$ or



5

wherein o is selected to an integer from 0 to 6,

and wherein

R^{12} and $R^{12'}$ are independently selected from the group consisting of:

10

-H and C_1 - C_6 -alkyl,

R^{13} and R^{14} are independently selected from the group consisting of

-H, C_1 - C_6 -alkyl,


-(CH_2) $_n$ - R^{16} , wherein n is selected to be an integer from 1 to 6

15

and R^{16} is selected from the group consisting of:

-OH, - NH_2 , or -CN,

-(CH_2) $_m$ - $CH=CH_2$, wherein m is selected to be an integer from 0 to 6,



20

wherein R^{17} is selected from the group consisting of -H, C_1 - C_6 -alkyl,

C_3 - C_6 -cycloalkyl,



phenyl substituted cyclopropyl, wherein the phenyl group is optionally substituted by one or two substituents R^{18} , and R^{18} is independently selected from the group consisting of:

-F, -Cl, -Br, -I, -CN, -OH, -NH₂,

R^{15} is selected from the group consisting of:

-H and C₁-C₆-alkyl,

or wherein R^4 and R^5 together form one of the ring systems represented by the formulas







and

R^{20} is independently selected from -F, -Cl, and -Br,

R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from the group consisting of:

H, C₁-C₆-alkyl, C₁-C₆-alkoxy, -F, -Cl, -Br, -I, -OH, -CN, -NR¹²R^{12'}, -N=N-R¹³, -NH-C(O)-R¹⁴, -NO₂, -C≡C-R¹⁵, -C(R²⁰)₃, or -CH(R²⁰)₂ or




wherein o is selected to an integer from 0 to 6, and

wherein R^{12} , $R^{12'}$, R^{13} , R^{14} , R^{15} , and R^{20} represent groups as defined for R^3 to R^6 , and

or wherein

R^8 and R^9 together form a ring system represented by the formulas



and/or pharmaceutically acceptable salts thereof.

2. Compound according to claim 1, wherein

5 R^1 is selected from the group consisting of -H or C_1 - C_4 -alkyl, and preferably is -H or methyl.


3. Compound according to claim 1 or 2, wherein

R^2 is selected from the group consisting of -H or C_1 - C_4 -alkyl, and preferably is -H.

10 4. Compound according to any one of claims 1 to 3, wherein

R^3 , R^4 , R^5 and R^6 are independently selected from the group consisting of:

-H, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, phenoxy, -F, -Cl, -Br, -I, -OH, -CN, - $NR^{12}R^{12'}$, -NH-C(O)- R^{14} , - NO_2 , - CF_3 , or



wherein o is selected to an integer from 0 to 4, preferably from 2 to 4, most preferably is 3,

and wherein

R^{12} and $R^{12'}$ are independently selected from the group consisting of -H or methyl,


R^{14} is selected from the group consisting of

C_1 - C_6 -alkyl,

-(CH_2) $_m$ -CH=CH $_2$, wherein m is selected to be an integer from 0 to 2 and preferably is 0,


cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, and phenyl substituted cyclopropyl,

or wherein R^4 and R^5 together form a ring system represented by the formula




5. Compound according to any one of claims 1 to 4, wherein R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from the group consisting of:


5 -H, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, -F, -Cl, -Br, -I, -OH, -N=N- R^{13} ,
 -NH-C(O)- R^{14} , -NO₂, -C≡C-H,



,



, or



;


wherein

10 R^{13} and R^{14} are independently selected from the group consisting of

C_1 - C_6 -alkyl, and preferably are methyl or ethyl,
 -(CH₂)_n- R^{16} , wherein n is selected to be an integer from 1 to 6 and R^{16} is selected from the group consisting of:

15 -NH₂ and -CN,


-CH=CH₂,



wherein R^{17} is selected from the group consisting of

20 -H and methyl,
 cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
 phenyl substituted cyclopropyl,

or wherein R⁸ and R⁹ together form one of the ring systems represented by the formulas



- 5 6. Compound according to any one of claims 1 to 5, wherein
R³ and R⁶ represent -H and
R⁴ and R⁵ are independently selected from the group consisting of:
-H, C₁-C₄-alkyl, and preferably are -H or methyl.
- 10 7. Compound according to any one of claims 1 to 6, wherein
R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are independently selected from the group
consisting of:
-H, C₁-C₆-alkyl, C₁-C₆-alkoxy, -F, -Cl, -Br, -I, -OH, -CN, and -
NR¹²R^{12'},
15 wherein R¹² and R^{12'} are independently selected from -H or
methyl and preferably are both -H.
8. Compound according to any one of claims 1 to 7, wherein
R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are independently selected from the group
consisting of:
20 -H, -F, -Cl, -Br, and -I.
9. Compound according to any one of claims 1 to 8, wherein
at least two of the groups R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are -H, preferably three or
two of the groups R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are -H.
- 25 10. Compound according to any one of claims 1 to 9, wherein four of the groups
R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are -H
11. Compound according to any one of claims 1 to 10, wherein R⁷, R⁹, R¹⁰, and
30 R¹¹ are -H, or wherein R⁷, R¹⁰ and R¹¹ are -H, or wherein R⁸ and R¹⁰ are -H.

12. Compound according to any one of claims 1 to 11, wherein those groups out of the group R^7 , R^8 , R^9 , R^{10} , and R^{11} which are not -H are selected from the group consisting of -F, -Cl, -Br and -I.

- 5 13. Compound according to any one of the preceding claims, wherein the compound is selected from the group consisting of:
- (Compound 1:) (3-Nitro-phenyl)-quinazolin-4-yl-amine,
(Compound 2:) (3-Bromo-phenyl)-quinazolin-4-yl-amine,
(Compound 3:) (6,7-Dimethoxy-quinazolin-4-yl)-[(3-(3,5-dimethyl-isoxazol-
10 4-ylazo)-phenyl]-amine,
(Compound 4:) Furan-2-carboxylic acid [4-(6,7-dimethoxy-quinazolin-4-yl-amino)-phenyl]-amide,
(Compound 5:) Furan-2-carboxylic acid [3-(6,7-dimethoxy-quinazolin-4-yl-amino)-phenyl]-amide,
(Compound 6:) 2-Cyano-*N*-[4-(6,7-dimethoxy-quinazolin-4-yl-amino)-
15 phenyl]acetamide,
(Compound 7:) 2-Cyano-*N*-[3-(6,7-dimethoxy-quinazolin-4-yl-amino)-phenyl]acetamide,
(Compound 8:) (3-Bromo-phenyl)-(6-methoxy-quinazolin-4-yl)-amine,
(Compound 9:) (3-Bromo-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
20 (Compound 10:) 6-Amino-hexanoic acid [4-(6,7-dimethoxy-quinazolin-4-yl)-phenyl]-amide,
(Compound 11:) 6-Amino-hexanoic acid [3-(6,7-dimethoxy-quinazolin-4-yl)-phenyl]-amide,
(Compound 12:) (3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine,
25 (Compound 13:) (6,7-Dimethoxy-2-methyl-quinazolin-4-yl)-(3-nitro-phenyl)-amine,
(Compound 14:) (6,7-Dimethoxy-2-methyl-quinazolin-4-yl)-(4-nitro-phenyl)-amine,
(Compound 15:) *N*-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-
30 propionamide,
(Compound 16:) (3-Bromo-phenyl)-(6,7-diethoxy-quinazolin-4-yl)-amine,
(Compound 17:) (6,7-diethoxy-quinazolin-4-yl)-(3-hydroxy-phenyl)-amine,

(Compound 18:) *N*-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-
propargylamide,

(Compound 19:) (3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-
amine,

5 (Compound 20:) *N*⁴-(3-Bromo-phenyl)-*N*⁶-methyl-quinazoline-4,6,7-triamine,

(Compound 21:) (3-Bromo-4-methoxy-phenyl)-(6,7-dimethoxy-quinazolin-4-
yl)-amine,

(Compound 22:) *N*⁴-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine,

(Compound 23:) (3,5-Bis-trifluormethyl-phenyl-quinazolin-4-yl)-amine,

10 (Compound 24:) (4-Fluoro-phenyl)-(6-methyl-quinazolin-4-yl)-amine,

(Compound 25:) (3-Chloro-phenyl)-(6-methyl-quinazolin-4-yl)-amine,

(Compound 26:) (6-Methyl-quinazolin-4-yl)-phenyl-amine,

(Compound 27:) (3,4-Dimethyl-phenyl)-(6-methyl-quinazolin-4-yl)-amine,

(Compound 28:) (2-Hydroxy-4-methyl-phenyl)-(6-methyl-quinazolin-4-yl)-
15 amine,

(Compound 29:) (6,7-Dimethoxy-quinazolin-4-yl)-(4-fluoro-phenyl)-amine,

(Compound 30:) (3,4-Dimethyl-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-
amine,

(Compound 31:) (4-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine,

20 (Compound 32:) Benzo[1,3]-dioxol-5-yl-(6,7-dimethoxy-quinazolin-4-yl)-
amine,

(Compound 33:) (3-Bromo-phenyl)-(6,7-dimethoxy-2-methyl-quinazolin-4-
yl)-amine,

(Compound 34:) (3-Chloro-5-hydroxy-phenyl)-(6-methyl-quinazolin-4-yl)-
25 amine,

(Compound 35:) *N*-[4-(Quinazolin-4-yl-amino)-phenyl]-acetamide,

(Compound 36:) Phenyl-[4-(quinazolin-4-yl-amino)-phenyl]-methanone,

(Compound 37:) (3,4-Dichloro-phenyl)-quinazolin-4-yl-amine,

(Compound 38:) (4-Chloro-2-hydroxy-phenyl)-quinazolin-4-yl-amine,

30 (Compound 39:) (2-Hydroxy-4-methyl-phenyl)-quinazolin-4-yl-amine,

(Compound 40:) (3,4-Dimethyl-phenyl)-quinazolin-4-yl-amine,

(Compound 41:) Benzo[1,3]-dioxol-5-yl-(6-methyl-quinazolin-4-yl)-amine,

(Compound 42:) (3-Chloro-4-methyl-phenyl)-(6-methyl-quinazolin-4-yl)-
amine,

(Compound 43:) (4-Bromo-phenyl)-(6-methyl-quinazolin-4-yl)-amine,

(Compound 44:) *N*-[4-(6-Methyl-quinazolin-4-yl-amino)-phenyl]-acetamide,

(Compound 45:) (4-Iodo-phenyl)-(6-methyl-quinazolin-4-yl)-amine,

(Compound 46:) Phenyl-[4-(6-methyl-quinazolin-4-yl-amino)-phenyl]-
methanone,

(Compound 47:) (4-Phenoxy-phenyl)-quinazolin-4-yl-amine,

(Compound 48:) (3-Hydroxy-phenyl)-(6-methyl-quinazolin-4-yl)-amine,

(Compound 49:) (3,4-Dichloro-phenyl)-(6-methyl-quinazolin-4-yl)-amine,

(Compound 50:) *N*-[4-(8-Methyl-quinazolin-4-yl-amino)-phenyl]-acetamide,

(Compound 51:) (4-Iodo-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 52:) (4-Phenoxy-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 53:) (3,4-Dichloro-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 54:) Benzo[1,3]-dioxol-5-yl-(8-methyl-quinazolin-4-yl)-amine,

(Compound 55:) (3-Chloro-4-methyl-phenyl)-(8-methyl-quinazolin-4-yl)-
amine,

(Compound 56:) (4-Bromo-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 57:) (3,4-Dimethoxy-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 58:) (3-Chloro-6-hydroxy-phenyl)-(8-methyl-quinazolin-4-yl)-
amine,

(Compound 59:) (2-Methoxy-4-methyl-phenyl)-(8-methyl-quinazolin-4-yl)-
amine,

(Compound 60:) (4-Chloro-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 61:) (8-Methyl-quinazolin-4-yl)-phenyl-amine

(Compound 62:) (3-Chloro-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 63:) (4-Fluoro-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 64:) (3,5-Bis-fluoromethyl-phenyl)-(8-methyl-quinazolin-4-yl)-
amine,

(Compound 65:) (3-Bromo-phenyl)-(8-methyl-quinazolin-4-yl)-amine,

(Compound 66:) (3,5-Bis-fluoromethyl-phenyl)-(6-methyl-quinazolin-4-yl)-
amine,

(Compound 67:) (4-Chloro-phenyl)-(6-methyl-quinazolin-4-yl)-amine,

(Compound 68:) Phenyl-[4-(8-methyl-quinazolin-4-yl-amino)-phenyl]-
methanone,

(Compound 69:) (3-Bromo-phenyl)-(7-fluoro-quinazolin-4-yl)-amine,

(Compound 70:) (3-Chloro-phenyl)-(7-fluoro-quinazolin-4-yl)-amine,
(Compound 71:) (3-Ethyl-phenyl)-quinazolin-4-yl-amine,
(Compound 72:) (4-Iodo-phenyl)-quinazolin-4-yl-amine,
(Compound 73:) (4-Phenoxy-phenyl)-quinazolin-4-yl-amine,
5 (Compound 74:) (4-Fluoro-phenyl)-(7-fluoro-quinazolin-4-yl)-amine,
(Compound 75:) (3-Fluoro-phenyl)-quinazolin-4-yl-amine,
(Compound 76:) (2,4-Dichloro-phenyl)-quinazolin-4-yl-amine,
(Compound 77:) (3-Hydroxy-phenyl)-quinazolin-4-yl-amine,
(Compound 78:) (3-Fluoro-4-methyl-phenyl)-(6-methyl-quinazolin-4-yl)-
10 amine,
(Compound 79:) (3-Fluoro-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
(Compound 80:) (3-Chloro-6-methyl-phenyl)-(7-fluoro-quinazolin-4-yl)-
amine,
(Compound 81:) Biphenyl-4-yl-quinazolin-4-yl-amine,
15 (Compound 82:) (3,4-Dimethoxy-phenyl)-quinazolin-4-yl-amine,
(Compound 83:) (6-Fluoro-quinazolin-4-yl)-(2-methyl-phenyl)-amine,
(Compound 84:) Phenyl-quinazolin-4-yl-amine,
(Compound 85:) (3-Chloro-6-methyl-phenyl)-quinazolin-4-yl-amine,
(Compound 86:) (4-Ethyl-phenyl)-quinazolin-4-yl-amine,
20 (Compound 87:) (3-Chloro-phenyl)-quinazolin-4-yl-amine,
(Compound 88:) (4-Fluoro-phenyl)-quinazolin-4-yl-amine,
(Compound 89:) (3-Ethyl-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
(Compound 90:) (7-Fluoro-quinazolin-4-yl)-phenyl-amine,
(Compound 91:) (3-Chloro-2-methyl-phenyl)-(6-methyl-quinazolin-4-yl)-
25 amine,
(Compound 92:) (4-Butyl-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
(Compound 93:) (4-Hydroxy-6-methyl-phenyl)-quinazolin-4-yl-amine,
(Compound 94:) (3-Nitro-6-methyl-phenyl)-quinazolin-4-yl-amine,
(Compound 95:) (3-Chloro-2-methyl-phenyl)-quinazolin-4-yl-amine,
30 (Compound 96:) (4-Ethyl-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
(Compound 97:) (4-Chloro-6-methyl-phenyl)-quinazolin-4-yl-amine,
(Compound 98:) (4-Bromo-phenyl)-quinazolin-4-yl-amine,
(Compound 99:) (3-Chloro-6-methyl-phenyl)-(8-methyl-quinazolin-4-yl)-
amine,

- (Compound 100:) (3-Chloro-6-methyl-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
- (Compound 101:) (3,4-Dimethoxy-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
- 5 (Compound 102:) (3,4-Dimethoxy-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine,
- (Compound 103:) (6-Methyl-quinazolin-4-yl)-(4-trifluoromethyl-phenyl)-amine,
- (Compound 104:) (2-Fluoro-phenyl)-(7-fluoro-quinazolin-4-yl)-amine,
- 10 (Compound 105:) (3-Chloro-phenyl)-(6,7-dimethoxy-2-methyl-quinazolin-4-yl)-amine,
- (Compound 106:) (6,7-Dimethoxy-quinazolin-4-yl)-(3-trifluoromethyl-phenyl)-amine,
- (Compound 107:) (3-Bromo-phenyl)-(6-nitro-quinazolin-4-yl)-amine,
- 15 (Compound 108:) Biphenyl-4-yl-(8-methyl-quinazolin-4-yl)-amine,
- (Compound 109:) (8-Methyl-quinazolin-4-yl)-(4-trifluoromethyl-phenyl)-amine,
- (Compound 110:) (2,4-Dichloro-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
- (Compound 111:) (4-Trifluoromethyl-phenyl)-quinazolin-4-yl-amine,
- 20 (Compound 112:) (2,3-Dimethyl-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
- (Compound 113:) (3,5-Bistrifluoromethyl-phenyl)-(7-fluoro-quinazolin-4-yl)-amine,)
- (Compound 114:) (2,4-Dimethyl-phenyl)-(6-methyl-quinazolin-4-yl)-amine,
- (Compound 115:) Benzo[1,3]-dioxol-5-yl-quinazolin-4-yl-amine,
- 25 (Compound 116:) (6,7-Dimethoxy-quinazolin-4-yl)-(4-nitro-phenyl)-amine,
- (Compound 117:) (6-Methyl-quinazolin-4-yl)-(2,4,5-Trichloro-phenyl)-amine,
- (Compound 118:) (3-Chloro-5-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine,
- 30 (Compound 119:) (3-Bromo-phenyl)-(6-nitro-7-fluoro-quinazolin-4-yl)-amine,
- (Compound 120:) N⁴-(3-Bromo-phenyl)-6-nitro-quinazoline-4,7-diamine,

(Compound 121:) *N*-[4-(3-Bromo-phenylamino)-7-cyclobutane-carbonylamino-quinazolin-6-yl]-cyclobutanecarboxylic acid amide,

(Compound 122:) *N*-[4-(3-Bromo-phenylamino)-7-cyclopentane-carbonylamino-quinazolin-6-yl]-cyclopentanecarboxylic acid amide,

(Compound 123:) *N*-[7-Acetylamino-5-(3-bromo-phenylamino)quinazolin-6-yl]-acetamide,

(Compound 124:) 3-(6,7-dimethoxy-quinazolin-4-yl-amino-benzonitrile,

(Compound 125:) (3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine.

and/ or pharmaceutically acceptable salts thereof.

14. Compound according to any one of claims 1 to 13 for use as a pharmaceutically active agent.
- Use of at least one compound according to claim 1 or 13 as a pharmaceutically active agent.
16. Use according to claim 15 for the prophylaxis and/ or treatment of infectious diseases, including opportunistic diseases.
17. Use according to claim 16, wherein the infectious disease is caused by herpes viruses.
18. Use according to claim 17, wherein the herpes virus is selected from the group comprising: herpes simplex viruses, varicello viruses, cytomegalo viruses, muromegalo viruses, roseolo viruses, lymphocrypto viruses and rhadino viruses.
19. Use according to claim 18, wherein the herpes virus is a cytomegalo virus.

20. Use according to claim 19, wherein the herpes virus is human cytomegalo virus (HCMV).
21. Use of at least compound according to claims 1 to 13 for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases.
22. Use according to claim 21, wherein said infectious disease is caused by herpes viruses.
23. Use according to claim 22, wherein the herpes virus is selected from the group comprising: herpes simplex viruses, varicello viruses, cytomegalo viruses, muromegalo viruses, roseolo viruses, lymphocrypto viruses and rhadino viruses.
24. Use according to claim 23, wherein the herpes virus is a cytomegalo virus.
25. Use according to claim 24, wherein the herpes virus is human cytomegalo virus (HCMV).
26. Use according to any one of claims 15 to 25, wherein said infectious disease is herpes.
27. Use according to any one of claims 15 to 26, wherein the herpes virus is a drug resistant virus strain.
28. Use of at least one compound according to claim 1-13 as an inhibitor for a protein kinase.
29. Use according to claim 28, wherein the protein kinase is a herpesviral kinase.
30. Use according to claim 29, wherein the herpesviral kinase is UL 97.

31. Use according to any one of claims 15 to 24, wherein the compound according to any one of claims 1 to 13 is administered in a dosage corresponding to an effective concentration in the range of 0.01 – 50 μ m.
- 5 32. Use according to any one of claims 15-31, wherein at least one compound according to any one of claims 1 to 13 is administered in combination with further therapeutic compounds.
- 10 33. Use according to claim 32, wherein the further therapeutic compounds are selected from the group consisting of:
Ganciclovir®, foscarnet®, cidofovir®, valganciclovir®, ganciclovir® implants, fomivirsen®, penciclovir® and valaciclovir®.
- 15 34. Pharmaceutical composition comprising at least one compound according to claim 1 to 13 as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
- 20 35. Pharmaceutical composition according to claim 34 further comprising an additional therapeutic agent selected from the group consisting of:
Ganciclovir®, foscarnet®, cidofovir®, valganciclovir®, ganciclovir® implants, fomivirsen®, penciclovir® and valaciclovir®.
- 25 36. Method for preventing and/or treating infectious diseases, including opportunistic diseases in a mammal, especially in a human, which method comprises administering to the mammal an amount of at least one compound as defined in any one of claims 1 to 13, effective to prevent and/or treat said infectious disease and/or opportunistic infection.
- 30 37. Method according to claim 36, wherein said infectious disease is caused by a herpes virus.
38. Method for preventing and/or treating herpesviral infections and/or associated diseases in a mammal, including a human, by administering a pharmaceutically effective amount of at least one compound as defined in any

one of claims 1 to 13 to said mammal, wherein said compound inhibits at least partially the activity of a herpesviral kinase, preferably of UL 97.

- 5 39. Method according to any one of claims 36 to 38, wherein the herpes virus is selected from the group comprising herpes simplex viruses, varicello viruses, cytomegalo viruses, muromegalo viruses, roseolo viruses, lymphocrypto viruses and rhadino viruses.
- 10 40. Method according to any one of claims 36 to 39, wherein the herpes virus is a cytomegalo virus.
41. Method according to claim 40, wherein the herpes virus is human cytomegalo virus.
- 15 42. Method according to any one of claims 39 to 41, wherein the herpes virus is a drug resistant virus strain.
43. Method according to any one claims 36 to 42, wherein said infectious disease or herpesviral infection is herpes.
- 20 44. Method according to any one of claims 36 to 43, wherein the compound according to claims 1 to 13 is administered in a dosage corresponding to an effective concentration in the range of 0.01 – 50 μm .
- 25 45. Method according to claims 36 to 44, wherein at least one compound according to claims 1 to 13 is administered in combination with at least one further therapeutic compound, selected from the group consisting of Ganciclovir®, foscarnet®, cidofovir®, valganciclovir®, ganciclovir® implants, fomivirsen®, penciclovir® and valaciclovir®.